Immunoclin (Immunoclin) Debt-to-Equity : 0.00 (As of Oct. 2014)

Immunoclin Debt-to-Equity Chart

Immunoclin Quarterly Data
	May11	Aug11	Nov11	Feb12	May12	Aug12	Nov12	Feb13	May13	Aug13	Nov13	Apr14	Jul14	Oct14
Debt-to-Equity	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Immunoclin's Debt-to-Equity

For the Biotechnology subindustry, Immunoclin's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunoclin's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunoclin's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Immunoclin's Debt-to-Equity falls into.

Immunoclin Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Immunoclin's Debt to Equity Ratio for the fiscal year that ended in Jan. 2014 is calculated as

Immunoclin's Debt to Equity Ratio for the quarter that ended in Oct. 2014 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunoclin  (GREY:IMCL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Immunoclin Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Immunoclin's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunoclin (Immunoclin) Business Description